Fundraising Fox
Onkure Therapeutics Inc
NASDAQ: OKURBoulder, US · Founded 2014 · Delaware corporation · 42 employees on LinkedIn · 7 known investors
Find your way into Onkure Therapeutics Inc
Sign up to see every warm intro you have to Onkure Therapeutics Inc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Onkure Therapeutics Inc team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
Founders & leadership
Board
Investors · 7
How we know: Access Biotechnology's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$159.4M disclosed across 4 rounds · 2017–2024
▶$65MraisedOct 2024 · 20 investors · PharmaceuticalsRule 506(b)
- Isaac MankeDirector
- Jason LeveroneExecutive Officer
- Samuel AgrestaExecutive Officer
- Dylan HartleyExecutive Officer
- Edward T. MathersDirector
- Nicholas SaccomanoExecutive Officer, Director
- Valerie M. JansenDirector
- R. Michael CarruthersDirector
- Michael G. GreyDirector
- Andrew Johm PhillipsDirector
- Offering amount
- $65M
- Amount sold
- $65M
- Sales commissions
- $3.3M
- Placement agents
- LifeSci Capital, LLC, Leerlink Partners LLC, Evercore Group, L.L.C
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$47.4MraisedDec 2020 · 15 investors · PharmaceuticalsRule 506(b)
- Gregory FlesherExecutive Officer, Director
- Lon Cardon, Ph.D.Director
- Michael GreyDirector
- Johan Kordel, Ph.D.Director
- Ed MathersDirector
- Niall O'Donnell, Ph.D.Director
- Wendy JohnsonExecutive Officer
- Alejandro Dorenbaum, M.D.Executive Officer
- Kenneth HarrisonDirector
- Bali MuralidharDirector
- Stacey SeltzerDirector
- Mike CruseExecutive Officer
- Offering amount
- $94.8M
- Amount sold
- $47.4M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedMay 2019 · 9 investors · PharmaceuticalsRule 506(b)
- Michael GreyDirector
- Niall O'Donnell, Ph.D.Executive Officer, Director
- Lon Cardon, Ph.D.Director
- Ed MathersDirector
- Johan Kordel, Ph.D.Director
- Art PappasDirector
- Wendy JohnsonExecutive Officer
- Alejandro Dorenbaum, M.D.Executive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$22MraisedJan 2018 · 16 investors · PharmaceuticalsRule 506(b)
- Scott WeinerDirector
- Wendy JohnsonExecutive Officer
- Michael GreyExecutive Officer, Director
- Niall O'DonnellExecutive Officer, Director
- Ed MathersDirector
- Offering amount
- $52M
- Amount sold
- $22M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 3
Companies working in the same space as Onkure Therapeutics Inc.
Frequently asked questions
- What does Onkure Therapeutics Inc do?
- OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
- Who are Onkure Therapeutics Inc's investors?
- Onkure Therapeutics Inc's investors include Access Biotechnology, Boulder Ventures, RiverVest Venture Partners, Abingworth, ACORN BIOVENTURES, New Enterprise Associates (NEA), Novo Holdings.
- How much funding has Onkure Therapeutics Inc raised?
- Onkure Therapeutics Inc has disclosed $159.4M raised across 4 rounds.
- Where is Onkure Therapeutics Inc headquartered?
- Onkure Therapeutics Inc is headquartered in Boulder, US.